INVITATION. INTERNATIONAL CONFERENCE TO CELEBRATE THE 50 th ANNIVERSARY OF HUNGARIAN SOCIETY FOR EXPERIMENTAL AND CLINICAL PHARMACOLOGY PROGRAM

Transcription

1 INVITATION INTERNATIONAL CONFERENCE TO CELEBRATE THE 50 th ANNIVERSARY OF HUNGARIAN SOCIETY FOR EXPERIMENTAL AND CLINICAL PHARMACOLOGY PROGRAM September 19 21, 2012 Organized by the Hungarian Society for Experimental and Clinical Pharmacology and The Section of Medical Sciences of the Hungarian Academy of Sciences

2

3 Venues September 19: The Main Building of the Hungarian Academy of Sciences, 1051 Budapest, Széchenyi István tér 9. web site: September 20 21: Hotel Sofitel Budapest Chain Bridge, 1051 Budapest, Széchenyi István tér 2. web site: budapest.com Main Patrons József Pálinkás, President, Hungarian Academy of Sciences Miklós Szócska, Minister of State for Health Patrons László Vécsei, President, Section of Medical Sciences of the Hungarian Academy of Sciences Ágoston Szél, Rector, Semmelweis University Organization Committee Zsuzsanna Fürst chair Beáta Sperlágh Kornélia Tekes Ádám Vas Valéria Kecskeméti Klára Gyires Hungarian Society for Experimental and Clinical Pharmacology Conference website: 3

4 PROGRAM Wednesday Lecture Hall of the Main Building of Hungarian Academy of Sciences Opening ceremony Welcome addresses Ingolf Cascorbi, representative of IUPHAR and the German Pharmacological Society Filippo Drago, President of EPHAR Thomas Griesbacher, President Elect of EPHAR, representative of APHAR Folke Sjöquist, representative of EACPT Patrizia Romualdi, representative of the Italian Pharmacological Society László Vécsei, President, Section of Medical Sciences of the Hungarian Academy of Sciences Tibor Ertl, President, Association of Hungarian Medical Societies MOTESZ Péter Gaszner, President, Hungarian Association for Psychopharmacologists László Fésüs, President, Hungarian Biochemical Society Zoltán Vincze, President, Hungarian Society for Pharmaceutical Sciences Béla Merkely, President, Hungarian Society of Cardiology István Kiss, President, Hungarian Society of Hypertension László Hunyady, President, Hungarian Physiological Society Honorary member ceremonies Thomas Griesbacher, Dirk van Helden, Pál Pacher, Patrizia Romualdi, Vinod P. Shah, Sándor Szabó

5 15 00 Lectures József Knoll Member of the Hungarian Academy of Sciences founder and honorary president for life of the Hungarian Society for Experimental and Clinical Pharmacology The enhancer regulation in the mammalian brain. Synthetic enhancer substances: deprenyl/selegiline and R ( ) 1 (benzofuran 2 yl) 2 propylaminopentane / ( ) BPAP E. Sylvester Vizi Former president of the Hungarian Academy of Sciences former president of the Hungarian Society for Experimental and Clinical Pharmacology From the bioassay of acetylcholine to the two photon laser scanning microscopy Ingolf Cascorbi Chair of the Pharmacogenetics Section of IUPHAR Pharmacogenomics and Epigenomics of Drug Resistance Music performance 5 Opera arias by pupils of Éva Marton Liszt Ferenc Academy of Music, Budapest Piano: Katalin Alter Gabriela Balgová: Gioachino Rossini La Cenerentola Aria of Cenerentola Non piú mesta Gyula Rab: Gaetano Donizetti L'elisir d'amore, "Una furtiva lagrima" (Aria of Nemorino, Act II, Scene II)

6 Szilvia Vörös: Pietro Mascagni Cavalleria Rusticana Aria of Santuzza "Voi lo sapete o mamma" Ildikó Emese Jakab: Giacomo Puccini La Boheme Si, mi chiamano Mimi (Aria of Mimi from the Act I) Ildikó Emese Jakab and Gyula Rab: Giacomo Puccini La Boheme O soave fanciulla (Duett of Mimi and Rodolpho from the Act I) Hotel Sofitel, Terrasse Restaurant Reception Thursday Hotel Sofitel, Vaszary Hall I. EPHAR Symposium: Neurodegeneration Organizer/Chair: Kálmán Magyar and Peter Riederer Peter Riederer Clinic and Policlinic for Psychiatry, Psychosomatic and Psychotherapy, University of Würzburg, Würzburg, Germany Unilateral onset of Parkinson s disease triggered by developmental disturbances? Moussa Youdim Technion Rappaport Family Faculty of Medicine, Eve Topf and US National Parkinson Foundation Centers of Excellence for Neurodegenerative Diseases, Haifa, Israel Why neuroprotective neurorestorative multi target for neurodegenerative disorders?

7 László Vécsei Department of Neurology, University of Szeged, Szeged, Hungary Kynurenines: possible drug development strategies for the treatment of CNS disorders Coffee break II. New trends in antinociceptive therapy Organizer/Chair: Zsuzsanna Fürst and János Szolcsányi Patrizia Romualdi Department of Pharmacology, University of Bologna, Bologna, Italy Does addiction occur in opiate pain treatment? Zsuzsanna Fürst Department of Pharmacology and Pharmacotherapy, Semmelweis University, Budapest, Hungary My way: Opioid Research János Szolcsányi Department of Pharmacology and Pharmacotherapy, University of Pécs, Pécs, Hungary Advent of a new chapter of analgesics Lunch break 7

8 III. New drug targets in CNS disorders Organizer/Chair: Beáta Sperlágh and Peter Illes Maria Pia Abbracchio Department of Pharmacological Sciences, University of Milan, Milan, Italy The dual purinergic/cysteinyl leukotriene receptor GPR17 as a new therapeutic target for demyelinating diseases Peter Illes Rudolf Boehm Institut für Pharmakologie und Toxikologie der Universität Leipzig, Leipzig, Germany P2X3 receptors; a new pharmacological target for the treatment of inflammatory and neuropathic pain Beáta Sperlágh Institute of Experimental Medicine, Hungarian Academy of Sciences, Budapest, Hungary P2Y12 receptor antagonists: new potential CNS indications beyond the antithrombotic effect Coffee break IV. Cardiovascular pharmacology Organizer/Chair: András Varró and Peter Ferdinandy

9 Pál Pacher National Institute on Alcohol Abuse and Alcoholism, National Institutes of Health, Rockville, Maryland, USA Role of the endocannabinoid system and natural nonpsychoactive cannabinoids in diabetic cardiovascular complications András Varró Department of Pharmacology and Pharmacotherapy, University of Szeged, Szeged, Hungary Possible new mechanisms of arrhythmia therapy Peter Ferdinandy Department of Pharmacology and Pharmacotherapy, Semmelweis University, Budapest, Hungary Cardioprotection in hyperlipidemia: role of inhibition of matrix metalloproteinase activity V. Gastrointestinal/smooth muscle pharmacology Organizer/Chair: Klára Gyires and Loránd Barthó Sándor Szabó School of Medicine, University of California, Irvine, VA Long Beach Healthcare System, Long Beach, CA, USA Novel pharmacologic approaches to treat gastrointestinal ulcers 9

10 Dirk F. van Helden The Neuroscience Group, School of Biomedical Sciences and Pharmacy, The University of Newcastle, Callaghan, New South Wales, Australia Slow wave rhythmicity and propagation in gastric smooth muscle Klára Gyires Department of Pharmacology and Pharmacotherapy, Semmelweis University, Budapest, Hungary Gastric mucosal defense: from periphery to CNS Loránd Barthó Department of Pharmacology and Pharmacotherapy, University of Pécs, Pécs, Hungary In vitro smooth muscle effects of compounds acting at TRP channels Organ concert in St. Anne s Church, Pest (1052 Budapest, Szervita tér 6.) Organist: Prof. János Borvendég Friday Hotel Sofitel, Vaszary Hall VI. Pharmacokinetics and drug metabolism Organizer/Chair: Imre Klebovich and Huba Kalász

11 Vinod P. Shah International Pharmaceutical Federation, SIG, Chair of Regulatory Sciences Pharmacokinetics in Drug Development and Regulations Georg Petroianu Department of Cellular Biology & Pharmacology, Herbert Wertheim College of Medicine, Florida International University, Miami, FL, USA Pyridinium Oximes for Reactivation of Phosphylated Cholinesterases: Is [clinical] disappointment rooted in pharmacokinetics? Huba Kalász Department of Pharmacology and Pharmacotherapy, Semmelweis University, Budapest, Hungary Regulation of Blood Brain Barrier penetration of polar organic compounds: Rules and Facts Coffee break VII. Clinical pharmacology Organizer/Chair: Csaba Farsang and Ádám Vas Folke Sjöquist Department of Laboratory Medicine, Division of Clinical Pharmacology, Karolinska Institutet, Karolinska University Hospital, Stockholm, Sweden 11

12 Forty years with clinical pharmacology in research, teaching and health care Gonzalo Calvo Rojas Department of Clinical Pharmacology, Hospital Clinic, University of Barcelona (UB), Barcelona, Spain The new EU regulatory framework. Practical implications for drug evaluation Csaba Farsang Cardiometabolic Center, Department of Internal Medicine, Szent Imre Hospital, Budapest, Hungary What we have learned and what we did not from clinical trials? Closing remarks TECHNICAL INFORMATION Lectures will be held in the Lecture Hall on the 2 nd floor of the Main Building of the Hungarian Academy of Sciences, and in the Vaszary Hall on the Basement of the Hotel Sofitel Chain Bridge. For speakers, LCD projector and a laptop with Windows XP Professional will be provided. There is no registration fee, but please send your intention of participation to rado.nikolett@koki.mta.hu

13 Main Building of the Hungarian Academy of Sciences 2. Hotel Sofitel Chain Bridge 3. St. Anne s Church, Pest SPONSORS 13

14

15 PharmAgora Quality of Life Cluster was established in by 11 SMEs from the pharmacology and life science industries. The main motive of shaping such cooperation was to cover a larger part of the pharmaceutical and health market, to be able to offer more complex services and to create a common platform that helps to strengthen market positions of the member companies. Thanks to the long time cooperation between the members, to the single market profile and to the precise realization of the innovative ideas the Cluster achieved significant results that were acknowledged by the Hungarian Pole Program Office by giving the Accredited Innovation Cluster title to PharmAgora. The most promising current running projects of the Cluster aim at such innovative areas as functional food products, nutritional supplements, drug combinations, corresponding instrument developments and clinical data management, biostatistics and comprehensive, rigorous quality assurance. A C T I V I T I E S Development and production of pre clinical research equipment and human diagnostic devices During the past 30 years Experimetria Ltd. has been developed continuously, that ensured its place on the world market. The company s product scale ranges from pre clinical research physiology, pharmacology, pathophysiology, applied anatomy experiments equipment till human diagnostic products Main products: HTP (High Through Put) Zebra fish measurement systems Cardiovascular diagnostic system: rest, stress and telemetry options EEG measurement system Muscle myography (MIG) system Clinical research organisation, monitoring, data management and biostatistics AdWare Research Ltd can undertake full scale management of clinical trials from application, selecting sites (phase I IV, GLP analytical site), till involving appropriate experts for conducting and monitoring trials in the area of pharmaceutical, dietary supplement, functional food, human medical devices and cosmetics research. The data management is provided by an own developed system that is in compliance with FDA 21 CFR Part 11. More information can be found at:

16